Condition: Fanconi Anemia · Head and Neck Squamous Cell Carcinoma · Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
This research study is a phase Ib/II, single-arm, non-randomized, non-blind, multicenter study designed to determine whether Afatinib is effective and safe in patients with locoregionally unresectable and / or metastatic HNSCC with Fanconi Anemia. The main hypothesis, based on preclinical evidence, is that treatment with afatinib, an epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), could be an effective treatment option to control cancer for patients with FA - HNSCC.
This description comes directly from the study's public registry record.
A Responsible Person Designated by the Sponsor · +34 93 434 44 12 · investigacion@mfar.net
Always discuss trial participation with your own doctor first.
| Medizinische Hochschule Hannover | Hanover, Germany | Recruiting |
| Hospital de la Santa Creu i Sant Pau | Barcelona, Catalonia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06648096